Literature DB >> 20209608

Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma.

Dimitrios Mougiakakos1, C Christian Johansson, Eric Trocme, Charlotta All-Ericsson, Mario A Economou, Olle Larsson, Stefan Seregard, Rolf Kiessling.   

Abstract

BACKGROUND: Forkhead box P3 (FOXP3)-positive regulatory T cells (Tregs) are key mediators of peripheral tolerance and suppress efficient antitumor responses. Prostaglandin E(2) (PGE(2)) produced by inducible cyclooxygenase-2 (COX-2) can lead to Treg induction. COX-2 expression has been linked to tumorigenesis and growth in various malignancies. The objective of the current study was to investigate whether Tregs infiltrate uveal melanomas (UMs) and whether their prevalence is linked to COX-2 expression and the prediction of overall survival (OS).
METHODS: One hundred patients who underwent enucleation after they were diagnosed with UM were included in the study. Immunohistochemical staining with monoclonal anti-FOXP3, anti-CD4, and anti-COX-2 antibodies was performed, and immunoreactivity was assessed. Correlations of COX-2 expression with the presence of Tregs, established clinicopathologic parameters, and OS were evaluated in univariate and multivariate analyses.
RESULTS: High expression of COX-2 was predictive of shortened OS. FOXP3-positive Tregs were detectable in 24% of UMs and were restricted to malignant tissue. The extent of COX-2 expression was associated significantly with Treg prevalence (P = .004) and Treg intratumoral localization (P = .005). Intratumoral Tregs (but not the prevalence of Tregs) were independent marker for worse OS with a hazard ratio of 5.36 in patients with COX-2-positive tumors.
CONCLUSIONS: The current results demonstrated that high COX-2 expression is associated with OS and Treg prevalence in UM. These findings are in line with the observations that COX-2/PGE(2) induces Tregs and that Tregs may alter antitumor responses, resulting in a negative effect on the clinical disease course. Intratumoral Tregs are an independent prognostic marker for COX-2-positive UM, and these results put COX-2 inhibitors and Treg depletion into the spotlight of potential novel treatment modalities for patients with UM. (c) 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20209608     DOI: 10.1002/cncr.24999

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

1.  Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.

Authors:  Fangxuan Li; Yang Zhao; Lijuan Wei; Shixia Li; Juntian Liu
Journal:  Cancer Biol Ther       Date:  2018-05-08       Impact factor: 4.742

Review 2.  Ocular diseases: immunological and molecular mechanisms.

Authors:  Jing Song; Yi-Fei Huang; Wen-Jing Zhang; Xiao-Fei Chen; Yu-Mian Guo
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

Review 3.  Regulatory T cells in the immunotherapy of melanoma.

Authors:  Zhengxiao Ouyang; Hongwei Wu; Linqin Li; Yi Luo; Xianan Li; Gang Huang
Journal:  Tumour Biol       Date:  2015-10-30

Review 4.  Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Authors:  Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal
Journal:  Pigment Cell Melanoma Res       Date:  2014-09-01       Impact factor: 4.693

5.  Conjunctival melanoma: association of cyclooxygenase-2 tumor expression to prognosis.

Authors:  Rita Pinto-Proença; Mariana Santos; Cristina Fonseca; Júlia Fernandes; Maria Filomena Gaspar; Rui Proença
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-01-02       Impact factor: 3.117

6.  Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.

Authors:  Pierre L Triozzi; Lynn Schoenfield; Thomas Plesec; Yogen Saunthararajah; Raymond R Tubbs; Arun D Singh
Journal:  Oncoimmunology       Date:  2014-10-31       Impact factor: 8.110

Review 7.  T regulatory cells in B-cell malignancy - tumour support or kiss of death?

Authors:  Camilla A Lindqvist; Angelica S I Loskog
Journal:  Immunology       Date:  2012-04       Impact factor: 7.397

Review 8.  Inflammation in uveal melanoma.

Authors:  I H G Bronkhorst; M J Jager
Journal:  Eye (Lond)       Date:  2012-12-14       Impact factor: 3.775

9.  Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.

Authors:  So-Woon Kim; Young Il Kim; Bilal Mustafa; Mi-Ju Kim; Gowun Jeong; Sung-Min Ahn; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim; Seung-Mo Hong; In Ja Park
Journal:  Mod Pathol       Date:  2020-07-24       Impact factor: 7.842

Review 10.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.